Trial Profile
A double-blind study of functional outcomes with atomoxetine-hydrochloride and placebo in adult outpatients with DSM-IV attention-deficit/hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2006
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Oct 2006 New trial record.